Rob Quinn is a highly experienced finance professional with a diverse background in various leadership roles within the life sciences and biotechnology sectors. Possessing a strong educational foundation with a 1st Class Honours degree in Cell and Molecular Biology from University College Dublin and a PhD in Biochemistry from The University of Manchester, Quinn has held positions such as Chief Financial Officer at multiple organizations, including PHARNEXT, BenevolentAI, MoA Technology, and the Aptamer Group. Additional experience includes key financial roles at Silence Therapeutics and GSK, as well as early career experience at Deloitte UK as a consultant. Currently, Quinn serves as Chief Financial Officer at MoA Technology and as Finance Trustee for Heal Rewilding.
This person is not in the org chart
This person is not in any teams
This person is not in any offices